文献速递骨质疏松与代谢性骨病创伤骨科

骨质疏松药物预防白人绝经后女性临床骨折:生存数据网状Meta分析

Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: a network meta-analysis of survival data.
PubMed 文献 · Osteoporos Int · 2020-01-30

该研究通过贝叶斯随机效应网状Meta分析,按有无现患椎体骨折(PVF)分层,比较不同骨质疏松药物预防白人绝经后女性临床骨折的疗效与耐受性。共纳入33项试验、79,144名绝经后女性,发现不同亚组有效药物不同,romosozumab是唯一在两组均能降低临床和椎体骨折的药物,而PTH(1-84)和abaloparatide耐受性低于安慰剂。

要点

  • PVF≥50%亚组中,特立帕肽、romosozumab、利塞膦酸、唑来膦酸和阿仑膦酸降低临床骨折风险。
  • 无PVF或PVF<50%亚组中,abaloparatide、romosozumab和地舒单抗降低临床骨折风险。
  • romosozumab是唯一在两组均降低临床和椎体骨折的药物;PTH(1-84)和abaloparatide耐受性差于安慰剂。

核心结论

  • 应根据绝经后女性有无现患椎体骨折选择不同的有效药物预防脆性骨折,romosozumab是唯一在两组均能降低临床和椎体骨折的药物。

研究设计与样本

  • 贝叶斯随机效应网状Meta分析,按现患椎体骨折(PVF)分层,纳入33项试验共79,144名绝经后女性。

主要发现

  • PVF≥50%亚组中,特立帕肽(HR 0.39,95%CI 0.28-0.57)、romosozumab(HR 0.49,95%CI 0.29-0.75)、利塞膦酸(HR 0.62,95%CI 0.50-0.79)、唑来膦酸(HR 0.67,95%CI 0.47-0.96)和阿仑膦酸(HR 0.69,95%CI 0.47-0.97)降低临床骨折风险。
  • 另一亚组中,abaloparatide(HR 0.56,95%CI 0.33-0.92)、romosozumab(HR 0.67,95%CI 0.47-0.95)和地舒单抗(HR 0.68,95%CI 0.50-0.85)降低临床骨折风险。
  • PVF≥50%亚组有5种药物降低椎体骨折风险,另一亚组有7种药物降低椎体骨折风险。
  • 除PTH(1-84)(RR 1.9,95%CI 1.4-2.6)和abaloparatide(RR 1.6,95%CI 1.2-2.3)外,所有药物均未增加退出风险。

关键数值与推荐

  • PVF≥50%亚组临床骨折HR:特立帕肽0.39(0.28-0.57)、romosozumab 0.49(0.29-0.75)、利塞膦酸0.62(0.50-0.79)、唑来膦酸0.67(0.47-0.96)、阿仑膦酸0.69(0.47-0.97)。
  • 另一亚组临床骨折HR:abaloparatide 0.56(0.33-0.92)、romosozumab 0.67(0.47-0.95)、地舒单抗0.68(0.50-0.85)。
  • 退出风险RR:PTH(1-84) 1.9(1.4-2.6)、abaloparatide 1.6(1.2-2.3),其余药物与安慰剂耐受性相同。

临床怎么用

  • 对白人绝经后女性,应根据有无现患椎体骨折选择骨质疏松药物以预防临床骨折。
  • romosozumab可考虑用于两类人群以同时降低临床和椎体骨折风险。
  • 使用PTH(1-84)或abaloparatide时需关注耐受性可能低于安慰剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: By Bayesian random effects network meta-analysis stratified by prevalent vertebral fracture (PVF), we conclude that different effective drugs should be used to prevent fragility fractures according to postmenopausal women with or without PVF and that there are two drugs (i.e., parathyroid hormone (1-84) and abaloparatide) less tolerated than placebo. INTRODUCTION: No studies have compared various osteoporosis drugs in postmenopausal women (PMW) either with or without prevalent vertebral fracture (PVF). We aimed to compare them in the two different subgroups. METHODS: We searched different databases to select relevant studies. We performed Bayesian random effects network meta-analysis to synthesize hazard ratio (HR) and 95% confidence interval (CI) for clinical fracture stratified by PVF and to synthesize risk ratio (RR) for tolerability and vertebral fracture. RESULTS: We included 33 trials involving 79,144 PMW. In the PVF ≥ 50% subgroup, teriparatide (HR 0.39, 95% CI 0.28-0.57), romosozumab (HR 0.49, 95% CI 0.29-0.75), risedronate (HR 0.62, 95% CI 0.50-0.79), zoledronate (HR 0.67, 95% CI 0.47-0.96), and alendronate (HR 0.69, 95% CI 0.47-0.97) reduced clinical fracture risk. In the other subgroup, abaloparatide (HR 0.56, 95% CI 0.33-0.92), romosozumab (HR 0.67, 95% CI 0.47-0.95), and denosumab (HR 0.68, 95% CI 0.50-0.85) reduced clinical fracture risk. Five drugs reduced vertebral fracture risk in the PVF ≥ 50% subgroup whereas seven did in the other subgroup. All drugs did not increase withdrawal risk except for parathyroid hormone (1-84) (PTH) (RR 1.9, 95% CI 1.4-2.6) and abaloparatide (RR 1.6, 95% CI 1.2-2.3). CONCLUSION: Different effective drugs should be used to prevent fragility fractures according to PMW with or without PVF, and romosozumab is the only one which can reduce clinical and vertebral fractures in both of the two populations. PTH and abaloparatide are less tolerated than placebo whereas the eight other drugs assessed in the study have the same tolerability as placebo.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Ding LL, Wen F, Wang H, et al. Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: a network meta-analysis of survival data. Osteoporos Int. 2020. PMID: 32002571. doi:10.1007/s00198-019-05183-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。